Why the study?
Post-infectious bronchiolitis obliterans is a rare chronic pediatric pulmonary disease with uncertain treatment options and limited success, prompting a characterization of cases diagnosed in 2023.
Population
11 patients diagnosed with PIBO in Ljubljana and Trieste
Design
Retrospective case series
Key result
Methylprednisolone treatment in 11 pediatric patients with post-infectious bronchiolitis obliterans following adenovirus infection resulted in clinical improvement in 9 patients (81.8%).
Authors
Loading...
Describes PIBO features in two small European cohorts; leaves open need for prospective multicenter studies before guiding care.
Observational (n=11)
Yes
A post-pandemic surge in pediatric PIBO cases following adenovirus infection showed clinical and radiological improvement with monthly high-dose methylprednisolone pulses.
Traunero et al. (2025) conducted an observational in Post-infectious bronchiolitis obliterans (PIBO) (n=11). Methylprednisolone was evaluated on Clinical improvement. Methylprednisolone treatment in 11 pediatric patients with post-infectious bronchiolitis obliterans following adenovirus infection resulted in clinical improvement in 9 patients (81.8%).